Ammonia levels after asparaginase in children
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 1 year old or older.
- You are being treated by a pediatric blood cancer doctor (pediatric hematology/oncology).
- You are currently receiving a medicine called recombinant Erwinia asparaginase for your cancer.
- You have not received this same medicine in the past two weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
This study is checking how long the cancer drug calaspargase stays active in the body. It aims to help doctors understand how to best use this medicine for children and young adults with acute lymphoblastic leukemia or lymphoma.
This research study examines how your immune system (specifically T cells) reacts to asparaginase, a drug used to treat acute lymphoblastic leukemia. By understanding these reactions, doctors hope to predict and prevent allergic or sensitivity problems during your cancer treatment.
This trial looks at the side effects of the drug asparaginase in children and young adults with certain types of leukemia or lymphoma. It aims to better understand and manage these side effects to improve treatment safety.
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
This trial tests a combination of chemotherapy drugs (DA-EPOCH) with or without rituximab, plus a special form of the enzyme asparaginase (JZP458), for adults with newly diagnosed B-ALL or T-ALL. It aims to offer an effective option for those who cannot have standard pediatric-style treatment, such as older adults.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.